Continue to content

In short

Venetoclax in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adult patients who are ineligible for intensive chemotherapy and who have no other suitable treatment option and are not eligible to participate in a clinical study for their serious condition.

For any questions, please contact be.mnp@abbvie.com

Information sheet

Member login required

This content is part of our learning materials for our members. Login or see our membership information

Login as a member

Access this content and your dashboard by logging in.
Login

Not a member yet?

more than 200 resources for doctors and nurses to epxlore.
See memberships

Relevant medical resources